Rosalind Scourse
Biographic Data
| ID | 9066447 |
|---|---|
| NAME | Rosalind Scourse |
| GIVEN NAMES | Rosalind |
| FAMILY NAME | Scourse |
| SIGNATURE | SCOURSE R |
| AFFILIATIONS | Médecins Sans Frontières |
| ORCID | 0000-0001-6171-0338 |
| VERIFIED | Yes |
| TOTAL WORKS | 2 |
| TOTAL CITATIONS | 0 |
| AUTHOR COUNT | 2 |
| EDITOR COUNT | 0 |
| FIRST PUBLICATION YEAR | 2025 |
| LATEST PUBLICATION YEAR | 2025 |
| H-INDEX | 0 |
Mpox exposes fundamental obstacles for vaccinating children in outbreaks
box Children could not be included in mpox vaccination roll-out within the first 100 days of the latest Mpox outbreak in the Democratic Republic of Congo and are yet to be rolled out in many countries with rising cases, despite this age group accounting for a large proportion of suspected cases and deaths
Cost analysis of the TB-PRACTECAL clinical trial on novel tuberculosis treatment regimens
Clinical trials are considered to be the largest contributor to pharmaceutical development costs. However, public disclosure of the costs of individual clinical trials is rare. Médecins Sans Frontières (MSF) sponsored a phase 2b-3 randomised controlled trial (TB-PRACTECAL), which identified a new treatment regimen for drug-resistant TB. We aimed to analyse the costs of undertaking a pivotal clinical trial conducted in relatively low-resource heal…
No prominent works on this page.
Mpox exposes fundamental obstacles for vaccinating children in outbreaks
box Children could not be included in mpox vaccination roll-out within the first 100 days of the latest Mpox outbreak in the Democratic Republic of Congo and are yet to be rolled out in many countries with rising cases, despite this age group accounting for a large proportion of suspected cases and deaths
Cost analysis of the TB-PRACTECAL clinical trial on novel tuberculosis treatment regimens
Clinical trials are considered to be the largest contributor to pharmaceutical development costs. However, public disclosure of the costs of individual clinical trials is rare. Médecins Sans Frontières (MSF) sponsored a phase 2b-3 randomised controlled trial (TB-PRACTECAL), which identified a new treatment regimen for drug-resistant TB. We aimed to analyse the costs of undertaking a pivotal clinical trial conducted in relatively low-resource heal…
Medicine (2 works) · Nursing (2 works) · Public health (2 works) · Accounting (1 work) · Bacillus and Francisella bacterial research (1 work) · Bedaquiline (1 work) · Biosimilars and Bioanalytical Methods (1 work) · Business (1 work) · Clinical trial (1 work) · Cost effectiveness (1 work)